BridgeBio Pharma (BBIO) PT Raised to $82 at UBS on ADH1 Optimism
Tweet Send to a Friend
UBS analyst Eliana Merle raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $82.00 (from $72.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
